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CORRESPONDENCE
Reactivation of Human Herpesvirus 6 Infection
in an Immunocompetent Host with Chronic
Encephalopathy
To the Editor—In a recent article, Razonable et al. [1] reported
a selective reactivation of human herpesvirus 6 (HHV-6) var-
iant A in critically ill immunocompetent patients. This reactiva-
tion, which was defined on the basis of the detection of HHV-6
DNA in peripheral blood lymphocytes, was observed in patients
who had been admitted to an intensive care unit for medical or
surgical indications or trauma, but it was not found in healthy
volunteers who represented the control group.
These findings led us to review the case of a 13-year-old girl
with chronic encephalopathy and whose recrudescence of
symptoms was associated with the reactivation of HHV-6 infec-
tion both at the systemic and central nervous system (CNS)
levels (i.e., detection of HHV-6 DNA in the blood and CNS).
Since 3 years of age, the subject had suffered from frequent epi-
leptic seizures that were resistant to treatment. At 8 years of age
she began to present cognitive deterioration.
At the time of our evaluation, the girl had 2 seizures per
month, and she was disoriented, amimic, and also showed inter-
mittent episodes of behavioral disorder. Her karyotype, blood
and urine screening for metabolic diseases, optic fundi, motor
and sensitive conduction velocity studies, immunoglobulins,
and T lymphocyte subsets (CD3, CD4, CD8, CD16, and
CD19) were normal.
Since both electroencephalogram and magnetic resonance
imaging findings were suggestive of a chronic encephalopathy
and since we could not exclude a possible CNS infection, we
performed a lumbar puncture, which yielded a clear cerebro-
spinal fluid (CSF) with normal values of glucose, protein, and
chloride and normal cell counts. A search for DNA sequences
of cytomegalovirus, HHV-6, herpes simplex virus 1 and 2, Ep-
stein-Barr virus, and varicella zoster virus was done, using a
nested polymerase chain reaction with homemade specific in-
ner and outer primers. CSF was only positive for HHV-6 se-
quences, which were also detected in peripheral blood mono-
nuclear cells. Serology for HHV-6, performed using an indirect
immunofluorescence assay, showed the presence of IgG anti-
bodies at a titer of 1:40 but no IgM antibodies. CSF was nega-
tive for both IgG and IgM antibodies. Serology for other com-
mon infectious agents (e.g., measles or rubeola) was not
suggestive of acute disease. Human immunodeficiency virus
serology was negative.
HHV-6 is a neurotropic virus; however, symptoms of neuro-
logic involvement, such as demyelination and seizures or status
epilepticus, have been observed in primary disease (i.e., ex-
anthema subitum) or in immunocompromised children [2, 3].
Our report suggests that HHV-6 reactivation at the CNS level
may occur in immunocompetent hosts with severe neurologic
disease. It remains to be defined whether, in our patient, viral re-
activation was the consequence of illness-related stress, as sug-
gested by Razonable et al. [1], or a factor contributing to the
recrudescence of CNS disease.
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Reply
To the Editor—We appreciate the interest of Arpino et al. [1]
in our recent study describing the selective reactivation of
human herpesvirus 6 (HHV-6) variant A in critically ill nonim-
munocompromised hosts [2]. Our study documented a 54%
HHV-6 reactivation in a cohort of patients admitted to the inten-
sive care unit for various indications, including 14 patients with
neurologic illness or injury. This novel observation prompted
Arpino et al. to review one of their patients who had a 10-year
history of undefined neurologic disease. In their report [1], Ar-
pino et al. describe the detection of HHV-6 in the peripheral
blood and cerebrospinal fluid (CSF) of a 13-year-old patient
with chronic encephalopathy. Using a “homebrew” nested poly-
merase chain reaction (PCR) assay, Arpino et al. support our
observation that HHV-6 can be detected during critical illness
even in immunocompetent hosts.
Arpino et al. further suggested that HHV-6 reactivation also
occurs in the central nervous system (CNS), as indicated by
the detection of HHV-6 DNA in CSF. Whether the detection
of HHV-6 in their patient is a reflection of illness-induced stress
or a direct cause of relapsing CNS disease is unclear. The neu-
rotropism of HHV-6 [3] has led to the evaluation of this virus
1843
as a direct or indirect cause of CNS disease. The role of primary
HHV-6 infection in benign febrile seizures in children [4] and
its influence in the pathogenesis of multiple sclerosis [5] has
been the subject of many studies. Whether it also causes chronic
encephalopathy, as suggested by Arpino et al., is an interesting
association that needs to be further investigated. In the cohort of
patients we investigated, 7 (50%) of the 14 patients with neuro-
logic illness or injury (e.g., seizures, cerebrovascular accident, or
neurosurgical procedures for intracerebral bleed and tumor ex-
cision) had HHV-6 reactivation. However, none had clinical ill-
ness similar to the case described by Arpino et al. Nevertheless,
the reactivation of HHV-6 in immunocompetent patients with
critical illness, whether systemically or within the confines of the
CNS, raises its potential significance in human clinical syndromes.
We have demonstrated elsewhere that HHV-6 reactivation
influences the pathogenesis of cytomegalovirus disease [6] and
causes distinct clinical illness in immunocompromised transplant
recipients [7]. In contrast, the clinical relevance of HHV-6 reac-
tivation in the immunocompetent host is yet to be defined. In
our study [2], HHV-6 reactivation was not associated with in-
creased morbidity or mortality. The observation by Arpino et al.
of HHV-6 reactivation (in the peripheral blood and in the CSF) in
a patient with chronic encephalopathy suggests that this virus
may play some role, whether directly or indirectly, in the clini-
cal illness described.
The detection of latent virus is a concern with the use of sen-
sitive qualitative PCR assays. While we do not underscore the
important observation by Arpino et al., the use of standardized
assays that could quantify virus load may be more useful, as
has been demonstrated in the diagnosis and management of cyto-
megalovirus infection [8]. With real-time detection, one could
also provide diagnostic testing with immediate relevance in the
clinical setting. The widespread application of this new technol-
ogy will undoubtedly unravel the still less-defined spectrum of
clinical illnesses due to HHV-6 reactivation. With its use, we
will be able to correlate the significance of the level of viral re-
activation with clinical illness progression or to monitor im-
provement with antiviral therapy.
In summary, current data suggest that HHV-6 reactivation
occurs even in immunocompetent patients. Whether its reacti-
vation in immunocompetent patients is related to specific clini-
cal syndromes and/or is just a reflection of the state of critical
illness is yet to be defined. As more evidence-based data is gath-
ered, with the increasing implementation of real-time quantita-
tive HHV-6 PCR assays, the spectrum of clinical illness resulting
from HHV-6 reactivation in both the immunocompromised and
immunocompetent hosts will be further elucidated.
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Impact of Protease Polymorphisms and Viral Fitness
on Human Immunodeficiency Virus (HIV) Type 1
Viremia in Untreated HIV-1 Infection
To the Editor—Perno et al. [1] found a high prevalence (52.8%)
of secondary protease mutations in 248 antiretroviral-naive pa-
tients. The strongest predictor of virologic failure was the pre-
sence of protease mutations at codons 10 and 36 (odds ratio,
2.2), and these mutations were observed in 39.3% and 40.0%
of patients, respectively. These results indicate that secondary
protease mutations occur frequently, are clinically important,
and may even justify the routine assessment of drug resistance
in treatment-naive individuals.
In a small pilot study, we found a large number of protease
polymorphisms in therapy-naive human immunodeficiency virus
(HIV) type 1–infected individuals and studied the hypothesis
that protease polymorphisms may affect viral fitness and de-
crease steady-state plasma HIV-1 viremia in antiretroviral-naive
patients. This hypothesis is based on observations that low levels
of plasma HIV-1 RNA in untreated HIV-1 infection strongly
predict a superior prognosis of HIV-1 infection [2]. In addition,
low plasma HIV-1 RNA levels have been associated with a more
favorable response to antiretroviral therapy [3].
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For this purpose, we selected 10 patients who had low, steady-
state HIV-1 loads (,104 copies/mL [median, 3.3 log10 copies/
mL], hereafter referred to as “low viremia”). These patients
were compared with 5 patients with high virus loads (.100,000
copies/mL, hereafter referred to as “high viremia”). All study
participants were antiretroviral naive and were in a chronic stage
of HIV-1 infection, without evidence of a primary illness. The
patients with low viremia had a mean age of 36 years, and 80%
(8/10) of them were male. They had a mean duration of known
HIV-1 seropositivity of 5.3 years and a median CD4 T cell count
of 323 cells/mL. The patients with high viremia had a mean
age of 37 years, and 80% (4/5) of them were male. They had a
mean duration of known HIV-1 seropositivity of 1.6 years and
a median CD4 T cell count of 223 cells/mL.
We sequenced the protease genes and performed 2 viral fit-
ness assays, using infectious viral recombinants that consisted
of the patient’s protease gene and the backbone of the laboratory
strain pNL4-3. Recombinant virus was cultivated, using the lym-
phocytic cell line CEM-SS, and virus production was quantified
every 2–3 days in the culture supernatant by a quantitative poly-
merase chain reaction method [4].
A total of 50 aa codons differed from those of wild-type virus
(table 1). All but 1 of the 15 patients showed at least 2 poly-
morphisms. The most frequent changes included mutations L63P/
T/S (8/15), R41K/T (5/15), I93L (5/15), T12K/S/D (4/15), I15V
(3/15), V77I/L (3/15), K14R (2/15), E35D (2/15), N37D/H (2/
15), Q61E/H (2/15), and I62V (2/15). Only 1 individual showed
a primary protease mutation at codon 46 [5]. Surprisingly, the
median number of protease mutations was 3 in both the high
and low viremia groups (P ¼ :77).
In the viral fitness assay, peak virus production was reached
after a median time of 11 days (range, 4–14 days), irrespective
of the high and low viremia classification. Median peak virus
production was 6.0 and 6.3 log10 copies/2.5 mL in the low and
high viremia groups, respectively (P ¼ :44). Using a second
method, which quantifies the tat-dependent long terminal repeat
activation by a colorimetric assay [4], we could confirm that the
peak virus expression was reached after a similar time period.
Conversely, a comparison of HIV-1 strains with good and poor
(cutoff, peak virus production of 3 £ 106 copies/2.5 mL) viral fit-
ness demonstrated that mutation L63P/T/S was more prevalent
in strains with reduced viral fitness (P ¼ :04). In contrast, other
protease mutations, such as R41K/T or I93L, did not show a rela-
tionship with the results of the viral fitness assay. Similarly, the
number of polymorphisms was not associated with viral fitness.
In conclusion, our results revealed that the number of protease
mutations, as well as individual protease mutations, cannot pre-
dict the steady-state viremia in untreated HIV-1–infected indi-
viduals, nor could we find a difference in viral fitness between
patients with low and high viremia. Instead, our results suggest
that the HIV-1–specific immune response, including different
patterns of chemokine receptors, may play the dominant role
and determine the magnitude of HIV-1 RNA levels in untreated
patients. In addition, mutations outside the protease region, which
have not been tested for, may affect viral replication. It has been
reported that mutations of the p6 Gag protein can influence Vpr
incorporation and reduce viral fitness [6]. Nevertheless, the
number of polymorphisms found in 10 patients with very low
virus loads was surprisingly high. Of importance, mutations at
codon 63 were found significantly more frequently in individ-
uals with lower peak virus production, and it is tempting to
speculate that this particular mutation affects viral fitness and
the subsequent responsiveness to antiretroviral therapy.
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Table 1. Protease mutations in 15 untreated human immunodefi-
ciency virus (HIV) type 1–infected patients, by level of virus load.
Level of HIV-1
load, patient no. Protease mutations
Low
1 I15V, L19I, L63P
2 K14R, I15V, E35D
3 T12K, R41K
4 K43R, I62V, L63T, A71V, V77L, I93L
5 T12S, L63S, V77I, I93L
6 K20Q, E35D, R41T, M46S, Q61H, L63P, E65Q
7 T12S, L63P
8 N37H, R41K, R57K, I93L
9 R41K, I93L
10 None
High
11 N37D, D60E, Q61E
12 K14R, L63P
13 I3F, T12D, I62V, L63P, I93L
14 I13V, L63P, V771
15 I15V, M36I, R41K, Y59H
NOTE. Patients with low viremia had ,104 HIV-1 RNA copies/mL; pa-
tients with high viremia had .100,000 HIV-1 RNA copies/mL.
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Identification of the Cryptosporidium Pig Genotype
in a Human Patient
To the Editor—The recent correspondence by Chalmers et al.
[1] supports our recent observations that unusual Cryptosporid-
ium parasites (C. meleagridis, C. felis, and C. canis) that are
normally associated with animals infect both immunocompro-
mised and immunocompetent humans [2]. In addition to the
identification of C. meleagridis in 19 immunocompetent patients
in England and Wales, Chalmers et al. also found 2 isolates
from 2 patients that did not seem to match any Cryptosporidium
parasites that have been found in humans, which suggests that
other unusual Cryptosporidium parasites may also infect hu-
mans. Herein, we describe the infection of a human immunode-
ficiency virus (HIV)–positive, but not severely immunosup-
pressed, individual with a Cryptosporidium parasite that
previously has been found in pigs: the Cryptosporidium pig geno-
type [3, 4].
The patient, a 24-year-old homosexual man who lived in Lima,
Peru, was enrolled on 27 April 2001 in an epidemiologic study
of enteric parasites in HIV-positive persons. HIV infection had
been diagnosed 8 months before study enrollment, and the
patient had no history of opportunistic infections and reported
no diarrheal illness at the time of enrollment or over the pre-
vious year. He reported no nausea, abdominal pain, vomiting,
or weight loss. The patient was receiving isoniazide prophylaxis
but not antiretroviral therapy. He reported having been sexually
active in the month prior to the interview, had had>2 sex part-
ners in the previous year, and admitted both active and passive
anal intercourse, using a barrier only some of the time. He had
a dog but reported no contact with other animals or animal ex-
creta, including pigs or pig feces. His CD4+ T cell count was
533 cells/mL on 3 May 2001.
Daily stool specimens were obtained from the patient on 28–
30 April and 12–14 May 2001, and, although he had no gastro-
intestinal symptoms, the specimen from 30 April was positive
for Cryptosporidium parasites, as determined by microscopic
examination of acid fast–stained slides. The intensity of infection
was scored as 1+ according to a system based on the number of
oocysts counted in a 20-mL volume of concentrated stool spec-
imen: 1+, 1–50 oocysts; 2+, 51–150 oocysts; and 3+, .150
oocysts per 20-mL volume. The rest of the stool specimens
were negative, as determined by microscopic examination in
Peru. The oocysts in the specimen appeared very similar in
shape and size to those of the C. parvum human and bovine ge-
notypes (shown in figure 1A). The oocysts were 5:05 £ 4:41 mm
in size (95% confidence limits [CLs], 0.07 and 0.08; n ¼ 56),
with a shape index (length-to-width ratio) of 1.15 (95% CL,
0.02). In contrast, C. parvum bovine genotype oocysts (n ¼ 44)
were 4:85 £ 4:39 mL in size (95% CLs, 0.05 and 0.04), with
a shape index of 1.11 (95% CL, 0.02), and C. parvum human
genotype oocysts (n ¼ 44) were 4:91 £ 4:28 mL in size (95%
CLs, 0.07 and 0.06), with a shape index of 1.15 (95% CL, 0.03).
The oocysts were reactive to 2 monoclonal antibodies (OW3
and OW50) against C. parvum bovine genotype [5], and they
stained bright green by fluorescein isothiocyanate–labeled anti-
bodies under an epifluorescence microscope.
Polymerase chain reaction (PCR) analysis of the small subunit
(SSU) rRNA gene [2] on the DNA extracted from the 30 April
2001 specimen (which was preserved in 2.5% potassium di-
chromate) resulted in positive amplification in all 6 PCR runs.
Restriction fragment– length polymorphism (RFLP) analysis
of all PCR products showed an RFLP banding pattern identical
to that of the Cryptosporidium pig genotype (figure 1B) [4]. DNA
sequence analysis of the PCR products produced an SSU rRNA
sequence identical to that of the Cryptosporidium pig genotype
(GenBank accession numbers AF108861 and AF115377), confirm-
ing the identification. The identification of the Cryptosporidium
pig genotype was further corroborated by PCR-RFLP analysis of
a frozen aliquot of the 30 April sample.
All 5 stool samples that were negative by microscopy were
made available for molecular analysis after the detection of
the Cryptosporidium pig genotype in the 30 April sample. The
sample obtained on 29 April 2001 tested positive in all 3 PCR
runs; however, the others did not produce any PCR product.
RFLP analysis of the PCR products from the 29 April sample
also showed the banding pattern of the Cryptosporidium pig
genotype. Subsequent analysis of the sample by immunofluo-
rescence at the Centers for Disease Control and Prevention
(Atlanta) revealed the presence of Cryptosporidium oocysts.
The implication of finding the Cryptosporidium pig genotype
in this patient is not entirely clear. Although the patient in this
study was HIV positive, he was not severely immunosuppressed,
as determined on the basis of his CD4+ T cell count (533 cells/
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mL), his medical history, and the absence of any symptoms of
illness. Other non–C. parvum Cryptosporidium parasites, such
as C. meleagridis, C. canis, and C. felis, initially were found in
HIV-positive persons and subsequently were found in immuno-
competent persons as well, many of whom did not have diarrhea
[2, 6–9]. Thus, immunosuppression may not be a prerequisite
for Cryptosporidium pig genotype infection in humans.
A parasite previously identified as C. muris was reported in
an HIV-positive patient [10], but the sequence of the SSU rRNA
gene from the parasite was more similar to that of C. andersoni
(a 2-bp difference in a 242-bp region) than to that of C. muris
(an 8-bp difference). Another 2 cases of C. muris– like crypto-
sporidiosis were reported in 2 healthy Indonesian girls, but little
evidence was presented to substantiate the identity of C. muris
[11]. Finding the Cryptosporidium pig genotype in humans sup-
ports the conclusion that other Cryptosporidium parasites are
likely to be found in humans as well as in certain epidemiologic
settings.
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